All In Biotech

Drug Trial Radar · NCT01704079

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Nov 2012

Primary completion

Aug 2014

Study completion Sep 2014

Sponsor

Lead sponsor
OPKO IP Holdings II, Inc.Industry
Sponsor type
Industry
First posted
Oct 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

Conditions

  • Chronic Kidney Disease
  • Hyperparathyroidism, Secondary
  • Vitamin D Deficiency

Interventions

  • CTAP101 30 μg capsulesDrug

    CTAP101 30 μg capsule taken daily at bedtime

  • Sugar pill to CTAP101 30 μg capsulesOther

    Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment BaselineTime frame: Approximately 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OPKO Renal

    Bannockburn, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.